PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Adamis Pharmaceuticals Corporation (ADMP)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00547W2089
CUSIP00547W208
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic

Highlights

Market Cap$7.25M
EPS-$10.14
Revenue (TTM)$5.02M
Gross Profit (TTM)-$1.43M
EBITDA (TTM)-$17.79M
Year Range$0.45 - $9.45
Target Price$0.42
Short %1.30%
Short Ratio0.02

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ADMP

Adamis Pharmaceuticals Corporation

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Adamis Pharmaceuticals Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%200.00%400.00%600.00%OctoberOct 08Oct 15Oct 22Oct 29Nov 05
-100.00%
676.67%
ADMP (Adamis Pharmaceuticals Corporation)
Benchmark (^GSPC)

S&P 500

Returns By Period


PeriodReturnBenchmark
Year-To-DateN/A10.16%
1 monthN/A3.47%
6 monthsN/A22.20%
1 yearN/A30.45%
5 years (annualized)N/A13.16%
10 years (annualized)N/A10.89%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2023-43.36%-14.94%-25.30%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Adamis Pharmaceuticals Corporation (ADMP) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ADMP
Adamis Pharmaceuticals Corporation
^GSPC
S&P 500
2.79

Sharpe Ratio


Rolling 12-month Sharpe Ratio-0.500.000.501.00OctoberOct 08Oct 15Oct 22Oct 29Nov 05
-0.40
0.88
ADMP (Adamis Pharmaceuticals Corporation)
Benchmark (^GSPC)

Dividends

Dividend History


Adamis Pharmaceuticals Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%OctoberOct 08Oct 15Oct 22Oct 29Nov 05
-100.00%
-9.37%
ADMP (Adamis Pharmaceuticals Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Adamis Pharmaceuticals Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Adamis Pharmaceuticals Corporation was 100.00%, occurring on Sep 25, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Nov 23, 19995876Sep 25, 2023
-73.29%Jun 11, 1996271Jul 7, 199795Nov 18, 1997366
-70.07%Nov 28, 1997191Sep 1, 1998296Nov 3, 1999487
-35.19%Aug 25, 199573Dec 12, 1995106May 16, 1996179
-9.72%May 29, 19961May 29, 19964Jun 4, 19965

Volatility

Volatility Chart

The current Adamis Pharmaceuticals Corporation volatility is 21.30%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%70.00%OctoberOct 08Oct 15Oct 22Oct 29Nov 05
21.30%
4.38%
ADMP (Adamis Pharmaceuticals Corporation)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Adamis Pharmaceuticals Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items